Is it possible to put an end to skepticism about "Covid-19" vaccines?

Finding an effective and safe vaccine against the "Covid-19" disease resulting from infection with the emerging corona virus, and the possibility of distributing that vaccine on a large enough scale to help stop the spread of the epidemic, is a top global priority today.

Because of the urgency of the vaccine, governments are doing their best to fund research and incentivize companies to ramp up trials, and pre-order doses, reduce regulatory barriers to the market, and grant manufacturers immunity from lawsuits related to injuries, Bloomberg News Agency reported. In the future, which is usually a high cost.

Even in light of the outbreak of a deadly pandemic such as the Corona epidemic, citizens' confidence in the vaccine is weak.

A poll conducted by the Ipsos Foundation for Opinion Polls during the months of July and August for the World Economic Forum concluded that while three out of four adults would like to receive a "Covid-19" vaccine if available, the Only 37 percent have a "strong" desire to do so.

It is noteworthy that the two most important reasons were mentioned about not wanting to get the vaccine, which are fear of side effects, and doubts about the effectiveness of the vaccine, without having any extreme feelings "against vaccination."

The swift approval of Russian President Vladimir Putin last month for the vaccine before the completion of large-scale trials on patients, a gamble that could actually lead to a setback for Russia's response to the "Covid-19" disease, according to "Bloomberg".

The Russian "Sputnik V" vaccine was approved for public use last August, before the results of the third phase studies of trials with it, a move that sparked widespread international criticism.

For his part, Putin said that experiments carried out on animals and volunteers showed that the vaccine leads to "stable immunity."

On the other hand, while the World Health Organization said that all vaccines should be conducted with the same medical studies.

In the United States, US President Donald Trump wants to launch a vaccine before the start of the elections, which raises fears that the green light in the end was a political decision rather than a decision based on comprehensive data.

On top of that, also comes the offer to provide legal immunity for manufacturers of vaccines and emergency treatments.

While this is useful in preventing companies from entering legal battles, it does not lead to building confidence among citizens.

While financial compensation is available, it is fully covered by taxpayers, to the amount of 311 thousand and 810 dollars, with a maximum for life, regardless of the type of injury, which is decided by a special committee without an opportunity to conduct a judicial review.

This has angered those who refuse to vaccinate rather than silence them.

And while the European Commission insists it will not waive safety or change liability rules, it has held that it is possible for governments to decide "certain" legal cases.

This had led to popular anger in the past.

During the outbreak of the H1N1 virus (known as swine flu) in 2009, many European governments took the risks of being responsible for providing rapid vaccines.

Thus, it is possible that the race to provide a vaccine for "Covid-19" disease may face some obstacles in the name of trust.

The need for large-scale patient trials has also not disappeared.

It is possible that providing more data and disclosing it to obtain approvals for public use could be in the interest of an important priority group, namely health care providers.

It must also be possible to maintain the provision of effective vaccine doses, without completely eliminating the responsibility of the manufacturers.

"Bloomberg" stated that there is an idea put forward by a British Institute of International Law and Comparative Law research project, to create a new compensation fund for "Covid-19" patients, designed to deal sympathetically and effectively with injury claims, without the need to go to court.

Instead of being fully funded by the taxpayer, it is possible for the private sector to partially finance it, thus ensuring that pharmaceutical companies play a role in the financing.

This will not put an end to the vaccine hesitancy overnight, but it may allay some concerns.